Abstract
Background: Secukinumab is a human immunoglobulin G1-kappa monoclonal antibody that targets and inhibits cytokine interleukin (IL)-17A. Secukinumab successfully treats conditions in which IL-17A plays a role, including psoriasis, psoriatic arthritis, and ankylosing spondylitis. While there are no reports of dangerous adverse effects with secukinumab treatment, there is a notable increase in nasopharyngitis and upper respiratory infections (URI). Herein we investigate potential mechanisms to explain the increased rates of URI amongst patients treated with secukinumab.
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
